Zamerovimab/Mazorelvimab

泽美洛韦单抗/玛佐瑞韦单抗

Report date: 2025/06/10 13:56:10

Base Information

Drug NameZamerovimab/Mazorelvimab
Drug Alias Name泽美洛韦玛佐瑞韦单抗克瑞毕SYN-023CTB-011/CTB-012CTB-012/CTB-011
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionRabies virus neutralization
TargetsRabies virus
Therapy Area/IndicationsZoonosesRabiesRhabdoviridae Infections +[7] 
Global Approved IndicationsRabies
Approved Indications in ChinaRabies
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/04
Country/TerritoryUnited StatesPhilippinesMacau +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSynermore Biologics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSynermore Biologics (Suzhou) Co Ltd
Inactive CompaniesLonn Ryonn Pharma Ltd
Active IndicationsRabiesRhabdoviridae InfectionsMononegavirales Infections +[6] 
Inactive IndicationsZoonoses

Other Information

ATC CodeN/A
Related LinksN/A